Article Information
History
- July 13, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 13, 2021 - 09:42).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ruben Rose1,†,
- Franziska Neumann2,†,
- Olaf Grobe2,
- Thomas Lorentz2,
- Helmut Fickenscher1 and
- Andi Krumbholz1,2,*
- 1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
- 2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
- ↵*Correspondence: krumbholz{at}infmed.uni-kiel.de; Tel.: +49-431-22010131
↵† These first authors contributed equally
Posted July 13, 2021.
Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme
